MHS Home/Alternate Site Infusion Services Ravulizumab-cwvz (Ultomiris) Infusion Order Set ALL ORDERS MUST BE SIGNED AND DATED BY PRESCRIBING PROVIDER **Patient Name:** DOB: Weight: _ lb/kg Patient Phone Number: (_ Requested Date of Service: _ **Patient Allergies:** Diagnosis: ICD - 10 Code: Z45.2: Encounter for adjustment and management of vascular access device Z95.828: Presence of other vascular implants and grafts Baseline Labs: none required Baseline Vaccination Required: Meningococcal vaccine at least 2 weeks prior to administering initial dose of Ravulizumab-cwvz (Ultomiris). Date given: ____/___ Additional Requirements: In addition to order, please include H&P with documentation to support diagnosis. Must include ICD-10 Code(s) and supporting labs. Patient must be enrolled in Ravulizumab-cwvz (Ultomiris) REMS program before starting. ** Emergency phone number for provider __ __ (required) ** Provider Order for Ravulizumab-cwvz (Ultomiris) Infusion ORDERS WITH CHECK When an order is optional (those with check boxes), providers are responsible for indicating a **BOXES** check mark in the box next to the order. Orders left unchecked will not be initiated. **<u>Biologic Infusion</u>**: Infuse via infusion pump via 0.22 micron in-line filter Ravulizumab-cwvz (Ultomiris) Weight: _ 40 to less than 60 kg: Loading dose = 2400 mg x1; Maintenance dose = 3000 mg every 8 weeks

- 60 to less than 100 kg: Loading dose = 2700 mg x1; Maintenance dose = 3300 mg every 8 weeks
- 100 kg or greater: Loading dose = 3000 mg x1; Maintenance dose = 3600 mg every 8 weeks

Loading Dose Infusion Recommendations Using 100 mg/mL (3 mL and 11 mL) yigls

Louding Book initial	Educing Book interior Recommendations coming 200 mg/m2 (6 m2 and 22 m2) vide					
Weight (kg)	Loading dose	Total volume to be	Minimum infusion time	Maximum infusion rate		
	(mg)	administered	(hrs)	(mL/hour)		
40 to <60 kg	2400 mg	48 mL	0.8 hrs	60 mL/hr		
60 to <100 kg	2700 mg	54 mL	0.6 hrs	90 mL/hr		
>/=100 kg	3000 mg	60 mL	0.4 hrs	150 mL/hr		

Maintenance Dose Infusion Recommendations Using 100 mg/mL (3 mL and 11 mL) vials

Weight (kg)	Loading dose	Total volume to be	Minimum infusion time	Maximum infusion rate
	(mg)	administered	(hrs)	(mL/hour)
40 to <60 kg	3000 mg	60 mL	0.9 hrs	67 mL/hour
60 to <100 kg	3300 mg	66 mL	0.7 hrs	95 mL/hour
>/=100 kg	3600 mg	72 mL	0.5 hrs	144 mL/hour

Additional Medications for vascular access maintenance:

- 0.9% NaCl (NS) PF flush in 10 mL syringe: Administer 5 30 mL IV as needed for establishing and maintaining IV access and for flushing IV line post infusion.
- Heparin: 100 units/mL for port OR 10 units/mL for other central line/midline, 3-5 mL PRN for de-accessing line.
- Cathflo (alteplase) 2 mg: Instill 2 mg (2 mL) into occluded catheter as needed for CVC/CVAD occlusion.

CONTINUED ON NEXT PAGE

FOR MHS HOME/ALTERNATE SITE INFUSION SERVICES USE ONLY				
Patient Identification:	Pre-printed order – Page 1 of 2			
Name:	Ravulizumab-cwvz (Ultomiris) Order Set			
MRN:	MultiCare			
DOB:				

Skilled Nurse to draw labs as follows:						
□ Lab(s): Frequency:						
Skilled Nurse Interventions:	(1) (1) (1)					
 Admit (first visit) patient to services for home infusion therapy of Ravulizumab-cwvz (Ultomiris). Complete Skilled Nurse Visit with each infusion for ongoing home infusion therapy of Ravulizumab-cwvz (Ultomiris). Obtain vital signs (TPR & B/P) at baseline and completion of infusion. 						
Obtain patient weight at each visit.						
Establish IV access and flush per policy to maintain patent	cy.					
Draw labs as ordered. A M. Draw labs as ordered.						
Add Ravulizumab-cwvz (Ultomiris) to sodium chloride 0.99 Informa Davidiana ab angle (Ultomiris) na garangila di	% (NS) bag (see page 1 for recommendations)					
 Infuse Ravulizumab-cwvz (Ultomiris) as prescribed. Once infusion complete, flush IV line with sodium chloride 	0.00% (NC) as proscribed					
 Once infusion complete, flush IV line with sodium chloride If vital signs are stable after infusion, Skilled Nurse will dis 						
Il vital signs are stable after infusion, Skilled Nurse will als	continue iv access and complete visit.					
$\frac{\textbf{If Hypersensitivity Reaction Develops}}{\textbf{The Skilled Nurse will:}} \ \textbf{(fever, chills, hypotension, hypotension)} \\$	rigors, itching, rash, etc.):					
STOP THE INFUSION.						
 Administer emergency medications as prescribed (below). 						
 Contact Emergency Medical Services (EMS/911) if indicate 	ed.					
 Increase vital sign monitoring to every 5 minutes. 						
 Contact provider via emergency phone number for addition 						
 Notify MHS Home/Alternate Site Infusion Pharmacist AND 	Nurse Supervisor.					
	1.16.1					
Emergency Medications: To be administered by skilled nurse as ne						
• Diphenhydramine 50mg/mL solution: Inject 0.5 mL (25 mg) into the vein via slow IV push over at least 2 minutes as needed for rash, itching, hives, flushing of skin, and/or mild-to-moderate hypersensitivity reaction. May give IM if no IV access is available.						
	125 ma/2 ml solution: Inject 2 ml (125 ma) into the vein as a					
 Methylprednisolone sodium succinate (SOLU-MEDROL) 125 mg/2 mL solution: Inject 2 mL (125 mg) into the vein as a slow IV push over at least 3 minutes once, as needed for hives, flushing of the skin, shortness of breath, chest tightness, tachycardia (HR>140 bpm), and/or moderate-to-severe hypersensitivity reaction. May give IM if no IV access is available. EPINEPHrine (Adrenalin) 1 mg/mL solution: Inject 0.3 mL (0.3 mg) intramuscular every 5-15 minutes as needed 						
	00 mg) by mouth as needed for fever (PRN for temperature >					
101F/38.3C) and/or mild-to-moderate hypersensitivity rea						
0.9% NaCl (NS) solution: Infuse 500 mL into the vein via g						
 Oxygen: Initiate oxygen by RN PRN chest pain or dyspned simple mask. 	a to keep SpO2>90%. For 1-6 LPM, use NC. For 6-10 LPM, use					
simple mask.						
Code Status: Please note, patients will be considered FULL Code	unless marked otherwise. If the patient has a POLST.					
advance directive or living will, please include a copy with the or						
Was consent obtained: □ Yes □ No (if yes, please send DOCUMENTATION of consent with order)						
I certify that this patient is safe and appropriate to receive therapy from Home Infusion Services.						
Provider Signature: Printed	Name: Date:					
NPI: Orders expire in 12 months unless otherwise specified:						
Due like (Clinical Section)	B					
Provider/Clinic Information:	Return completed orders to:					
Address	MultiCare Home/Alternate Infusion Services					
Address:	253-459-6650 (phone) / 253-864-2785 (fax)					
Phone #: Fax#:						
FOR MHS HOME/ALTERNATE SITE INFUSION SERVICES USE ONLY						
Patient Identification:	Pre-printed order – Page 2 of 2					
Name:	Ravulizumab-cwvz (Ultomiris) Order Set					

MultiCare

Revised 06/24

MRN:

DOB: